Based on the analysis of Amphastar's profitability, liquidity, and operating efficiency, Amphastar P is performing exceptionally good at this time. It has a great probability to report excellent financial results in April. As of now, Amphastar's Current Deferred Revenue is decreasing as compared to previous years. The Amphastar's current Retained Earnings is estimated to increase to about 597.2 M, while Common Stock Shares Outstanding is projected to decrease to under 43.9 M. Key indicators impacting Amphastar's financial strength include:
Investors should never underestimate Amphastar's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Amphastar's cash flow, debt, and profitability to make informed and accurate decisions about investing in Amphastar P.
Net Income
167.49 Million
Amphastar
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Change To Inventory
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Liabilities
Investments
Change Receivables
Net Borrowings
Total Cashflows From Investing Activities
Exchange Rate Changes
Dividends Paid
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Operating Activities
Other Cashflows From Investing Activities
Change To Netincome
Common Stock Shares Outstanding
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Long Term Debt
Cash And Short Term Investments
Net Receivables
Good Will
Common Stock Total Equity
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Short Term Debt
Intangible Assets
Common Stock
Property Plant Equipment
Net Tangible Assets
Noncontrolling Interest In Consolidated Entity
Retained Earnings Total Equity
Long Term Debt Total
Capital Surpluse
Deferred Long Term Liab
Short Long Term Debt
Treasury Stock
Non Current Liabilities Other
Deferred Long Term Asset Charges
Net Invested Capital
Net Working Capital
Capital Lease Obligations
Long Term Investments
Depreciation And Amortization
Interest Expense
Selling General Administrative
Selling And Marketing Expenses
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Net Income Applicable To Common Shares
Net Income From Continuing Ops
Non Operating Income Net Other
Tax Provision
Interest Income
Minority Interest
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Amphastar Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Amphastar's financial statements are interrelated, with each one affecting the others. For example, an increase in Amphastar's assets may result in an increase in income on the income statement.
Amphastar competes with Collegium Pharmaceutical, Alkermes Plc, Evolus, Neurocrine Biosciences, and Ironwood Pharmaceuticals. Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California. Amphastar Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 1761 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Amphastar's current stock value. Our valuation model uses many indicators to compare Amphastar value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Amphastar competition to find correlations between indicators driving Amphastar's intrinsic value. More Info.
Amphastar P is rated third in return on equity category among its peers. It is rated fifth in return on asset category among its peers reporting about 0.36 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Amphastar P is roughly 2.80 . As of now, Amphastar's Return On Equity is increasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Amphastar's earnings, one of the primary drivers of an investment's value.
Amphastar's Earnings Breakdown by Geography
Amphastar P Systematic Risk
Amphastar's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Amphastar volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Amphastar P correlated with the market. If Beta is less than 0 Amphastar generally moves in the opposite direction as compared to the market. If Amphastar Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Amphastar P is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Amphastar is generally in the same direction as the market. If Beta > 1 Amphastar moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Amphastar Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Amphastar's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Amphastar growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Amphastar help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Amphastar P. We use our internally-developed statistical techniques to arrive at the intrinsic value of Amphastar P based on widely used predictive technical indicators. In general, we focus on analyzing Amphastar Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Amphastar's daily price indicators and compare them against related drivers.
When running Amphastar's price analysis, check to measure Amphastar's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amphastar is operating at the current time. Most of Amphastar's value examination focuses on studying past and present price action to predict the probability of Amphastar's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amphastar's price. Additionally, you may evaluate how the addition of Amphastar to your portfolios can decrease your overall portfolio volatility.
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.